首页 | 本学科首页   官方微博 | 高级检索  
     


A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model
Authors:Castillo-Olivares Javier  Calvo-Pinilla Eva  Casanova Isabel  Bachanek-Bankowska Katarzyna  Chiam Rachael  Maan Sushila  Nieto Jose Maria  Ortego Javier  Mertens Peter Paul Clement
Affiliation:Institute for Animal Health, Pirbright, Woking, Surrey, United Kingdom. javier.castillo-olivares@bbsrc.ac.uk
Abstract:African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2).
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号